Tilray Brands (TLRY) Cash from Investing Activities (2017 - 2026)
Tilray Brands (TLRY) posted Cash from Investing Activities of $28.9 million for Q1 2026, up 149.85% on a QoQ basis from -$58.0 million in Q4 2025, and up 24400.0% year-over-year from N/an in Q1 2025.
Tilray Brands (TLRY) Cash from Investing Activities (2017 - 2026) Analysis & Trends
Tilray Brands' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at $28.9 million for Q1 2026.
- Quarterly Cash from Investing Activities rose 24400.0% year-over-year to $28.9 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $8.9 million (up 158.62% YoY) and the FY2025 annual result came in at -$46.7 million, down 136.4% from the prior year.
- Cash from Investing Activities was $28.9 million for Q1 2026 at Tilray Brands, up from -$58.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $81.5 million in Q4 2023 and bottomed at -$271.4 million in Q4 2022.
- A 5-year average of -$12.6 million and a median of -$1.5 million in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 3792.69% — and 2026, when it soared 24400.0%.
- Tilray Brands' Cash from Investing Activities stood at -$271.4 million in 2022, then jumped by 130.03% to $81.5 million in 2023, then sank by 113.16% to -$10.7 million in 2024, then sank by 440.84% to -$58.0 million in 2025, then soared by 149.85% to $28.9 million in 2026.
- Business Quant data shows TLRY's Cash from Investing Activities at $28.9 million in Q1 2026, -$58.0 million in Q4 2025, and $24.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.16 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.60 Bn | 12.18 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Tilray Brands | 452.95 Mn | 392.75 Mn | 54.95 Mn | 28.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 28.92 Mn |
| Feb 28, 2026 | 28.92 Mn |
| Nov 30, 2025 | -58.01 Mn |
| Nov 30, 2025 | -58.01 Mn |
| Aug 31, 2025 | 24.47 Mn |
| Aug 31, 2025 | 24.47 Mn |
| May 31, 2025 | 13.52 Mn |
| May 31, 2025 | 13.52 Mn |
| Feb 28, 2025 | -119,000.00 |
| Feb 28, 2025 | -119,000.00 |
| Nov 30, 2024 | -10.73 Mn |
| Nov 30, 2024 | -10.73 Mn |
| Aug 31, 2024 | -49.40 Mn |
| Aug 31, 2024 | -49.40 Mn |
| May 31, 2024 | 45.06 Mn |
| May 31, 2024 | 45.06 Mn |
| Feb 29, 2024 | 28.09 Mn |
| Feb 29, 2024 | 28.09 Mn |
| Nov 30, 2023 | 81.50 Mn |
| Nov 30, 2023 | 81.50 Mn |